Immix Biopharma Inc. held its Annual Meeting of stockholders on June 20, 2025. During the meeting, stockholders elected Ilya Rachman, Gabriel Morris, Jason Hsu, Magda Marquet, and Helen C. Adams as directors of the company. Additionally, the appointment of Crowe LLP as the company's independent registered public accounting firm for the year ending December 31, 2025, was ratified. Both proposals were approved by the stockholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.